Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 2/3 1

Status

Recruiting 3Not yet recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 128Colonic Neoplasms 54Rectal Neoplasms 48Carcinoma, Hepatocellular 29Neoplasm Metastasis 23Stomach Neoplasms 22Neoplasms 11Pancreatic Neoplasms 9Cholangiocarcinoma 8Adenocarcinoma Of Esophagus 8Esophageal Neoplasms 7Liver Neoplasms 6Biliary Tract Neoplasms 5Recurrence 4Ovarian Neoplasms 4Gastrointestinal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Esophageal Squamous Cell Carcinoma 3Digestive System Neoplasms 3Breast Neoplasms 3Adenocarcinoma 3Unresectable Metastatic Colorectal Cancer 2Peritoneal Neoplasms 2Neoplastic Cells, Circulating 2Intestinal Neoplasms 2Gastrointestinal Diseases 2Gallbladder Neoplasms 2Colorectal Cancer Metastatic 2Cirrhosis, Familial, with Pulmonary Hypertension 2Squamous Cell Carcinoma of Head and Neck 1

Interventions

Gemcitabine 91Cisplatin 69Oxaliplatin 37Capecitabine 37durvalumab 29Fluorouracil 26pembrolizumab 24Leucovorin 22S 1 (combination) 18Nivolumab 13Irinotecan 13lenvatinib 12Bevacizumab 11tremelimumab 10apatinib 8Trastuzumab 7Injections 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7Paclitaxel 6Immune Checkpoint Inhibitors 6Docetaxel 6titanium silicide 5surufatinib 5envafolimab 5camrelizumab 5atezolizumab 5Folfox protocol 5Drug Therapy 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × Folfox protocol × Clear all
NCT06529718 2026-05-19

SEVILLA

UNICANCER

Phase 2 Recruiting
72 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT07265674 2026-05-14

Beacon-BTC

J-Pharma Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07466238 2026-05-08

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Peking University

Phase NA Recruiting
40 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06919848 2025-04-09

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

Fudan University

Phase 2 Not yet recruiting
74 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Sun Yat-sen University

Phase 2/3 Not yet recruiting
206 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡